Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 148

Similar articles for PubMed (Select 23127989)

1.

Discovery of new scaffolds for rational design of HCV NS5B polymerase inhibitors.

Golub AG, Gurukumar KR, Basu A, Bdzhola VG, Bilokin Y, Yarmoluk SM, Lee JC, Talele TT, Nichols DB, Kaushik-Basu N.

Eur J Med Chem. 2012 Dec;58:258-64. doi: 10.1016/j.ejmech.2012.09.010. Epub 2012 Sep 17.

2.

Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase.

Talele TT, Arora P, Kulkarni SS, Patel MR, Singh S, Chudayeu M, Kaushik-Basu N.

Bioorg Med Chem. 2010 Jul 1;18(13):4630-8. doi: 10.1016/j.bmc.2010.05.030. Epub 2010 May 15.

3.

Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors.

Musmuca I, Caroli A, Mai A, Kaushik-Basu N, Arora P, Ragno R.

J Chem Inf Model. 2010 Apr 26;50(4):662-76. doi: 10.1021/ci9004749.

PMID:
20225870
4.

2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase.

Küçükgüzel I, Satılmış G, Gurukumar KR, Basu A, Tatar E, Nichols DB, Talele TT, Kaushik-Basu N.

Eur J Med Chem. 2013 Nov;69:931-41. doi: 10.1016/j.ejmech.2013.08.043. Epub 2013 Sep 12.

5.

Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors.

Therese PJ, Manvar D, Kondepudi S, Battu MB, Sriram D, Basu A, Yogeeswari P, Kaushik-Basu N.

J Chem Inf Model. 2014 Feb 24;54(2):539-52. doi: 10.1021/ci400644r. Epub 2014 Feb 5.

PMID:
24460140
6.

Discovery of N-arylalkyl-3-hydroxy-4-oxo-3,4-dihydroquinazolin-2-carboxamide derivatives as HCV NS5B polymerase inhibitors.

Deore RR, Chen GS, Chang PT, Chern TR, Lai SY, Chuang MH, Lin JH, Kung FL, Chen CS, Chiou CT, Chern JW.

ChemMedChem. 2012 May;7(5):850-60. doi: 10.1002/cmdc.201200058. Epub 2012 Mar 1.

PMID:
22383290
7.

Discovery of novel HCV polymerase inhibitors using pharmacophore-based virtual screening.

Kim ND, Chun H, Park SJ, Yang JW, Kim JW, Ahn SK.

Bioorg Med Chem Lett. 2011 Jun 1;21(11):3329-34. doi: 10.1016/j.bmcl.2011.04.010. Epub 2011 Apr 9.

PMID:
21531135
9.

Discovery of substituted N-phenylbenzenesulphonamides as a novel class of non-nucleoside hepatitis C virus polymerase inhibitors.

May MM, Brohm D, Harrenga A, Marquardt T, Riedl B, Kreuter J, Zimmermann H, Ruebsamen-Schaeff H, Urban A.

Antiviral Res. 2012 Aug;95(2):182-91. doi: 10.1016/j.antiviral.2012.04.008. Epub 2012 May 10.

PMID:
22580131
10.

I. Novel HCV NS5B polymerase inhibitors: discovery of indole 2-carboxylic acids with C3-heterocycles.

Anilkumar GN, Lesburg CA, Selyutin O, Rosenblum SB, Zeng Q, Jiang Y, Chan TY, Pu H, Vaccaro H, Wang L, Bennett F, Chen KX, Duca J, Gavalas S, Huang Y, Pinto P, Sannigrahi M, Velazquez F, Venkatraman S, Vibulbhan B, Agrawal S, Butkiewicz N, Feld B, Ferrari E, He Z, Jiang CK, Palermo RE, McMonagle P, Huang HC, Shih NY, Njoroge G, Kozlowski JA.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5336-41. doi: 10.1016/j.bmcl.2011.07.021. Epub 2011 Jul 19.

PMID:
21840715
11.

Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition.

Biswal BK, Wang M, Cherney MM, Chan L, Yannopoulos CG, Bilimoria D, Bedard J, James MN.

J Mol Biol. 2006 Aug 4;361(1):33-45. Epub 2006 Jun 16.

PMID:
16828488
12.

Identification of allosteric inhibitors blocking the hepatitis C virus polymerase NS5B in the RNA synthesis initiation step.

Betzi S, Eydoux C, Bussetta C, Blemont M, Leyssen P, Debarnot C, Ben-Rahou M, Haiech J, Hibert M, Gueritte F, Grierson DS, Romette JL, Guillemot JC, Neyts J, Alvarez K, Morelli X, Dutartre H, Canard B.

Antiviral Res. 2009 Oct;84(1):48-59. doi: 10.1016/j.antiviral.2009.06.009. Epub 2009 Jul 7.

PMID:
19589358
13.

Evaluation of coumarin and neoflavone derivatives as HCV NS5B polymerase inhibitors.

Nichols DB, Leão RA, Basu A, Chudayeu M, de Moraes Pde F, Talele TT, Costa PR, Kaushik-Basu N.

Chem Biol Drug Des. 2013 May;81(5):607-14. doi: 10.1111/cbdd.12105. Epub 2013 Apr 4.

PMID:
23311976
14.

Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype.

Beaulieu PL, Coulombe R, Duan J, Fazal G, Godbout C, Hucke O, Jakalian A, Joly MA, Lepage O, Llinàs-Brunet M, Naud J, Poirier M, Rioux N, Thavonekham B, Kukolj G, Stammers TA.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4132-40. doi: 10.1016/j.bmcl.2013.05.037. Epub 2013 May 23.

PMID:
23768906
15.

Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation.

Ryu K, Kim ND, Choi SI, Han CK, Yoon JH, No KT, Kim KH, Seong BL.

Bioorg Med Chem. 2009 Apr 15;17(8):2975-82. doi: 10.1016/j.bmc.2009.03.024. Epub 2009 Mar 18.

PMID:
19332375
16.

Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.

Hang JQ, Yang Y, Harris SF, Leveque V, Whittington HJ, Rajyaguru S, Ao-Ieong G, McCown MF, Wong A, Giannetti AM, Le Pogam S, Talamás F, Cammack N, Nájera I, Klumpp K.

J Biol Chem. 2009 Jun 5;284(23):15517-29. doi: 10.1074/jbc.M808889200. Epub 2009 Feb 26.

17.

Pyridobenzothiazole derivatives as new chemotype targeting the HCV NS5B polymerase.

Manfroni G, Meschini F, Barreca ML, Leyssen P, Samuele A, Iraci N, Sabatini S, Massari S, Maga G, Neyts J, Cecchetti V.

Bioorg Med Chem. 2012 Jan 15;20(2):866-76. doi: 10.1016/j.bmc.2011.11.061. Epub 2011 Dec 3.

PMID:
22197397
18.

The discovery and structure-activity relationships of pyrano[3,4-b]indole-based inhibitors of hepatitis C virus NS5B polymerase.

Jackson RW, LaPorte MG, Herbertz T, Draper TL, Gaboury JA, Rippin SR, Patel R, Chunduru SK, Benetatos CA, Young DC, Burns CJ, Condon SM.

Bioorg Med Chem Lett. 2011 Jun 1;21(11):3227-31. doi: 10.1016/j.bmcl.2011.04.052. Epub 2011 Apr 21.

PMID:
21550237
19.

Structural and regulatory elements of HCV NS5B polymerase--β-loop and C-terminal tail--are required for activity of allosteric thumb site II inhibitors.

Boyce SE, Tirunagari N, Niedziela-Majka A, Perry J, Wong M, Kan E, Lagpacan L, Barauskas O, Hung M, Fenaux M, Appleby T, Watkins WJ, Schmitz U, Sakowicz R.

PLoS One. 2014 Jan 9;9(1):e84808. doi: 10.1371/journal.pone.0084808. eCollection 2014.

20.

Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors.

Kaushik-Basu N, Bopda-Waffo A, Talele TT, Basu A, Costa PR, da Silva AJ, Sarafianos SG, Noël F.

Nucleic Acids Res. 2008 Mar;36(5):1482-96. doi: 10.1093/nar/gkm1178. Epub 2008 Jan 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk